EUVIMEDEUVIMED entdecken
Crossref

Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration

Sooyeon Lee, Hae Jung Sun, Sung Jin Lee, Kyung Seek Choi

Korean Journal of Ophthalmology · 04.11.2026

DOI: 10.3341/kjo.2026.0051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, online erschienen am 04.11.2026. Verfasst von Sooyeon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Age-related macular degenerationAnti-VEGFBrolucizumabIntravitreal injection

Autor:innen und Institutionen

  • Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. ckseek@schmc.ac.kr.

Zitieren

APA

Lee, S., Sun, H. J., Lee, S. J., & Choi, K. S. (2026). Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2026.0051

Vancouver

Lee S, Sun HJ, Lee SJ, Choi KS. Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. 2026. doi:10.3341/kjo.2026.0051

BibTeX
@article{Lee2026,
  author = {Lee, Sooyeon and Sun, Hae Jung and Lee, Sung Jin and Choi, Kyung Seek},
  title = {Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration},
  journal = {Korean Journal of Ophthalmology},
  year = {2026},
  doi = {10.3341/kjo.2026.0051}
}
Kostenlos starten →